

Ronnie Shapira-Frommer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/560001/publications.pdf>

Version: 2024-02-01

61
papers

11,198
citations

201674

27
h-index

161849

54
g-index

61
all docs

61
docs citations

61
times ranked

13964
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. <i>Cells</i> , 2022, 11, 1140.	4.1	8
2	Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. <i>Gynecologic Oncology</i> , 2022, 166, 211-218.	1.4	20
3	Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5606-TPS5606.	1.6	1
4	Better (a little) late than never: The impact of steroidal treatment initiation timing on the outcome of patients with melanoma treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9544-9544.	1.6	0
5	Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5506-5506.	1.6	8
6	BRAF-targeted therapy for locally advanced ameloblastoma of the mandible: A potential neoadjuvant strategy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3149-3149.	1.6	0
7	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. <i>Science</i> , 2021, 371, 602-609.	12.6	784
8	A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1284-1297.	2.6	28
9	Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 496-501.	1.4	7
10	Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. , 2021, 9, e001743.		23
11	Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5570-5570.	1.6	9
12	Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5599-TPS5599.	1.6	1
13	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 613-621.	10.7	44
14	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	1.4	7
15	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	2.8	9
16	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	1.4	20
17	Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. <i>European Journal of Cancer</i> , 2021, 157, 415-423.	2.8	18
18	526â€¦Removal of soluble tumor necrosis factors receptors 1/2 in patients with metastatic solid tumors using immune apheresis. , 2021, 9, A556-A556.		1

#	ARTICLE	IF	CITATIONS
19	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	1.6	1,740
20	O83...Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. , 2020, 8, A2.1-A2.		6
21	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology</i> , The, 2020, 21, 1353-1365.	10.7	1,363
22	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2329.	3.7	45
23	Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. <i>Molecular Carcinogenesis</i> , 2020, 59, 736-744.	2.7	24
24	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	7.0	132
25	Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6015-6015.	1.6	2
26	318...Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007. , 2020, , .		0
27	393...First-in-human phase 1/2a study of the novel nonfucosylated anti-CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results. , 2020, , .		2
28	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	3.7	32
29	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478.	1.6	671
30	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1396-1404.	2.5	19
31	Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients. <i>European Journal of Cancer</i> , 2019, 108, 61-68.	2.8	48
32	Efficacy and safety of niraparib as maintenance treatment in older patients (≤70–years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. <i>Gynecologic Oncology</i> , 2019, 152, 560-567.	1.4	35
33	A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11064-11064.	1.6	5
34	KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5595-TPS5595.	1.6	11
35	Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-190.	1.6	18
36	Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2018, 17, 284-289.	5.8	149

#	ARTICLE	IF	CITATIONS
37	Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Caseâ€“Control Study. <i>Cancer Immunology Research</i> , 2018, 6, 1453-1458.	3.4	35
38	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 1075-1085.	6.4	133
39	Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600â€“mutant metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 101, 229-235.	2.8	29
40	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. <i>JCI Insight</i> , 2018, 3, .	5.0	107
41	Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5511-5511.	1.6	45
42	Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5522-5522.	1.6	59
43	A Phase Iâ€“II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> Mutated Ovarian Carcinoma or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4095-4106.	7.0	213
44	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic <i>BRCA1</i> or <i>BRCA2</i> mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	1.4	222
45	Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3071-3071.	1.6	107
46	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1579-1589.	10.7	380
47	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. <i>British Journal of Cancer</i> , 2016, 115, 1313-1320.	6.4	52
48	Olaparib maintenance therapy in patients with platinumâ€“sensitive, relapsed serous ovarian cancer and a <i>BRCA</i> mutation: Overall survival adjusted for postprogression poly(adenosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	9
49	Efficacy and safety of olaparib monotherapy in germline <i>BRCA1 / 2</i> mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecologic Oncology</i> , 2016, 140, 199-203.	1.4	252
50	Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2016, 34, 5501-5501.	1.6	9
51	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2015, 33, 244-250.	1.6	1,473
52	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	10.7	1,419
53	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious <i>BRCA</i> mutation.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5513-5513.	1.6	12
54	What clinical factors influence advanced <i>BRCA1/2</i> mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?. <i>Journal of Clinical Oncology</i> , 2015, 33, 5546-5546.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. Journal of Clinical Oncology, 2015, 33, 5550-5550.	1.6	9
56	Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.. Journal of Clinical Oncology, 2015, 33, 5529-5529.	1.6	2
57	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 852-861.	10.7	1,237
58	Olaparib monotherapy in patients with advanced cancer and a germ-line <i>BRCA1/2</i> mutation: An open-label phase II study.. Journal of Clinical Oncology, 2013, 31, 11024-11024.	1.6	17
59	Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).. Journal of Clinical Oncology, 2013, 31, 5518-5518.	1.6	3
60	Adoptive Immunotherapy of Advanced Melanoma. Current Treatment Options in Oncology, 2012, 13, 340-353.	3.0	13
61	Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.. Journal of Clinical Oncology, 2012, 30, 5022-5022.	1.6	2